Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Varex Imaging (VREX) Q4 Earnings Preview: Flat Revenue and Modest EPS Dip Expected

Varex Imaging (VREX) Q4 Earnings Preview: Flat Revenue and Modest EPS Dip Expected

Key Takeaways

  • Varex Imaging is expected to report results for the fourth quarter of fiscal year 2026 shortly, with Wall Street consensus pointing to adjusted earnings per share (EPS) of roughly $0.33 on revenue near $229.8 million.
  • The projected figures compare against a strong prior-year quarter, when the company delivered non-GAAP EPS of $0.37 on revenue of $228.9 million, suggesting a roughly flat year-over-year top line and a modest decline in EPS.
  • Varex has topped consensus EPS estimates in seven of its last eight quarters, keeping the bar high for another positive surprise.
  • The Industrial segment — spanning security screening and cargo inspection systems — has become the key growth driver, while Medical demand continues to lean on computed tomography (CT) tube sales.
  • In its most recent quarter, the company beat EPS expectations but fell short on revenue, underscoring investor sensitivity to both profitability and top-line momentum.
  • For additional detail, you can explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
  • For automated, data-driven trade ideas, explore Trending AI Robots.

Why Varex Imaging's Upcoming Report Matters

Varex Imaging Corporation is a leading designer and manufacturer of X-ray imaging components — including X-ray tubes, digital detectors, and image-processing software — sold to medical original equipment manufacturers (OEMs), as well as industrial and security imaging customers. Because the company runs a non-standard fiscal calendar ending in early October, the upcoming report covers the fourth quarter of fiscal year 2026. This print matters because it closes the fiscal year and sets the tone for fiscal 2027. Investors are focused on whether the fast-growing Industrial segment can offset choppier Medical demand, and whether tariff and China-related pressures continue to weigh on gross margins. The results will also provide a first look at how management frames the coming year. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Analyst Expectations for the Quarter

For the fourth quarter of fiscal 2026, analysts tracked by MarketBeat expect Varex to post adjusted EPS of about $0.33 on revenue of approximately $229.8 million. That compares with non-GAAP EPS of $0.37 and revenue of $228.9 million in the same quarter a year earlier — implying expected EPS contraction of roughly 10.8% alongside essentially flat revenue growth of about 0.4%.

Varex does not typically issue detailed quarterly guidance for the full quarter ahead in the same format, so investors will lean on consensus and management commentary. Historically, the company has been a frequent EPS beater, exceeding consensus in seven of its last eight quarters. In its most recent report (the third quarter of fiscal 2026), Varex posted EPS of $0.31, beating the roughly $0.21 consensus, but revenue of $210.5 million missed the roughly $215.5 million estimate — a reminder that the market watches top-line execution as closely as the bottom line. From what I see, this pattern of beating on EPS while missing on revenue highlights the need to monitor both metrics closely.

Market Sentiment Ahead of the Print

Sentiment heading into the print is balanced between optimism about the Industrial segment's momentum and caution over Medical softness and margin headwinds. Varex shares have shown meaningful volatility around recent reports, particularly when results diverge across the two segments or when guidance signals pressure ahead. Management has previously flagged that tariffs are weighing on gross margins by an estimated 100 to 150 basis points, and that geopolitical dynamics between China and ex-China Medical sales remain a source of inconsistency. With customer concentration also high — the top 10 customers represented roughly 52% of fiscal 2025 revenue — investors will scrutinize any commentary on order trends and demand visibility across both segments.

Forward Factors Worth Watching

Beyond the headline numbers, investors should watch several forward-looking signals. The first is the trajectory of the Industrial segment, which has posted record quarterly revenue on the strength of security inspection and cargo systems. Sustained orders there would reinforce Varex's diversification story, while any slowdown could reset expectations for the new fiscal year.

Second, margin resilience will be a central theme. Tariff costs, product mix, and the ramp of new manufacturing capacity — including radiographic detector production from the company's facility in India — will all influence gross margin in the quarters ahead. Management's guidance on these items will likely matter as much as the reported figures themselves.

Third, watch the Medical segment, where CT tube demand has been a bright spot but oncology and other modalities have shown unevenness. Finally, balance sheet and cash flow trends deserve attention, given the company's earlier use of cash to retire convertible debt and the resulting decline in its cash position. Together, these factors will shape how the market interprets Varex's momentum entering fiscal 2027.

Exploring AI-Powered Research Tools

In my own analysis of names like Varex, I find it helpful to cross-reference earnings data with broader market signals. One resource I turn to regularly is Tickeron’s AI Screener, which allows filtering by technical patterns, fundamentals, and AI-driven signals to identify comparable opportunities or shifts in momentum during earnings season. It provides a structured way to scan for trade ideas without relying solely on manual review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VREX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


VREX in downward trend: 10-day moving average moved below 50-day moving average on November 10, 2026

The 10-day moving average for VREX crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VREX as a result. In 61 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.

VREX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VREX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

The Aroon Indicator for VREX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +0.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where VREX advanced for three days, in 195 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

VREX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. VREX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.577) is normal, around the industry mean (4.142). P/E Ratio (34.148) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (4.979) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.903) is also within normal values, averaging (40.124).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VREX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -14%. POAS experienced the highest price growth at 172%, while LFWD experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -44%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -49%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 62
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufactures of X-ray tubes, flat panel detectors, connectors and accessories for imaging as well as workstations and software for computer-aided diagnostics and image processing

Industry MedicalNursingServices

Industry
Medical Specialties
Address
1678 S. Pioneer Road
Phone
+1 801 972-5000
Employees
2400
Web
https://www.vareximaging.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.